SSA
NXTC icon

Schonfeld Strategic Advisors’s NextCure NXTC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,153
Closed -$6.36K – 2458
2025
Q2 		$6.36K Sell
1,153
-425
-27% -$2.28K ﹤0.01% 1960
2025
Q1 		$9.09K Sell
1,578
-239
-13% -$2.11K ﹤0.01% 2124
2024
Q4 		$16.8K Sell
1,817
-166
-8% -$2.44K ﹤0.01% 1898
2024
Q3 		$32.6K Sell
1,983
-317
-14% -$5.83K ﹤0.01% 1902
2024
Q2 		$43.9K Sell
2,300
-30,470
-93% -$593K ﹤0.01% 1948
2024
Q1 		$877K Buy
+32,770
New +$564K 0.01% 1284
2020
Q4 		– Sell
-5,600
Closed -$592K – 1782
2020
Q3 		$592K Buy
+5,600
New +$689K 0.01% 862
2020
Q1 		– Sell
-833
Closed -$563K – 1407
2019
Q4 		$563K Buy
+833
New +$418K 0.01% 703

Other funds holding NXTC

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CPA
Cardiff Park Advisors Carlsbad, California $1.25B AUM 24.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schonfeld Strategic Advisors's NXTC Position: Q3 2025 in Review

Schonfeld Strategic Advisors sold out of NextCure (NXTC) in Q3 2025, closing a stake of 1,153 shares — an estimated $6.36K sold.

Schonfeld Strategic Advisors first reported a position in NXTC in Q4 2019 and held it in 8 quarters. The position peaked at $877K in Q1 2024. 17 funds tracked by Wall St. Rank hold NXTC as of Q3 2025.

  • Schonfeld Strategic Advisors reported no remaining NextCure position as of Q3 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 1,153 NextCure shares in Q3 2025, an estimated $6.36K.
  • Schonfeld Strategic Advisors first reported a position in NextCure in Q4 2019 and held it in 8 quarters.
  • Schonfeld Strategic Advisors's NextCure position peaked at $877K in Q1 2024.
  • 17 funds tracked by Wall St. Rank held NextCure as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.